A new initiative has been launched with the goal of expediting the development and availability of messenger RNA (mRNA) vaccine candidates for human avian influenza (H5N1).
The World Health Organisation (WHO), alongside the Medicines Patent Pool (MPP), made this known in a joint statement published by WHO on Monday, stating that the H5N1 is for manufacturers in low and middle-income countries (LMICs).
It said Sinergium Biotech, an Argentinian manufacturer, will spearhead this effort, utilising the WHO and MPP mRNA technology transfer programme to achieve the objective.
mRNA technology transfer programme
According to the statement, the mRNA technology transfer programme, a collaborative endeavour between the WHO and MPP, was launched in July 2021 with the objective of enhancing capacity in LMICs for the development and production of mRNA-based vaccines.
Subscribe our newsletter to stay updated
Thank you for subscribing!
Subscribe our newsletter to stay updated
Thank you for subscribing!
